Adler A, Yaniv I, Steinberg R, Solter E, Samra Z, Stein J, Levy I
Unit of Paediatric Infectious Diseases and Hospital Infection Control, Schneider Children's Medical Center of Israel, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
J Hosp Infect. 2006 Mar;62(3):358-65. doi: 10.1016/j.jhin.2005.08.019. Epub 2006 Jan 10.
The aim of this study was to define and compare the infectious and non-infectious complications associated with Hickman catheters and implantable ports in children. The study was conducted over a three-year period in the Department of Haematology-Oncology at the Schneider Children's Medical Center of Israel. All patients who required a central venous catheter (CVC) were included in the study. For each episode of catheter-associated bloodstream infection, demographic, clinical and microbiology data were recorded. During the study period, 419 tunnelled CVCs (246 implantable ports and 173 Hickman) were inserted in 281 patients. Compared with implantable ports, Hickman catheters were associated with a significantly higher rate of bloodstream infections (4.656 vs 1.451 episodes per 1000 catheter-days), shorter time to first infection (52.31 vs 108.82 days, P < 0.001), shorter duration of catheterization (140.75 vs 277.28 days, P < 0.001), and higher rate of removal because of mechanical complications (P < 0.005). Gram-positive bacterial infections were more prevalent in the implantable port group (63.6% vs 41.6%), whereas Gram-negative rods, polymicrobial infections and mycobacterial infections were more prevalent in the Hickman group (31.4% vs 50.9%, 17% vs 36% and 0% vs 4.4%, respectively; P < 0.05 for all). Haematopoietic stem cell transplantation was identified as an independent risk factor for infection [odds ratio (OR) -1.68, P = 0.005] and for catheter removal due to complications (OR -2.0, P < 0.001). Implantable ports may be considered the preferred device for most paediatric oncology and stem cell transplantation patients.
本研究的目的是确定并比较儿童希克曼导管和植入式静脉输液港相关的感染性和非感染性并发症。该研究在以色列施耐德儿童医学中心血液肿瘤学系进行了三年。所有需要中心静脉导管(CVC)的患者均纳入研究。对于每例导管相关血流感染事件,记录人口统计学、临床和微生物学数据。在研究期间,281例患者共插入了419根隧道式CVC(246根植入式静脉输液港和173根希克曼导管)。与植入式静脉输液港相比,希克曼导管相关血流感染率显著更高(每1000导管日4.656次 vs 1.451次),首次感染时间更短(52.31天 vs 108.82天,P < 0.001),置管时间更短(140.75天 vs 277.28天,P < 0.001),因机械并发症而拔除的比例更高(P < 0.005)。革兰氏阳性菌感染在植入式静脉输液港组更为常见(63.6% vs 41.6%),而革兰氏阴性杆菌、多微生物感染和分枝杆菌感染在希克曼导管组更为常见(分别为31.4% vs 50.9%、17% vs 36%和0% vs 4.4%;所有P值均 < 0.05)。造血干细胞移植被确定为感染的独立危险因素[比值比(OR)-1.68,P = 0.005]以及因并发症导致导管拔除的独立危险因素(OR -2.0,P < 0.001)。对于大多数儿科肿瘤学和干细胞移植患者,植入式静脉输液港可能被视为首选装置。